NCT02389517 2026-01-22
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
University of Chicago
Phase 2 Completed
Clinical Trials
54 trialsNCT02619682 2026-01-08
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT02461888 2025-12-17
MUKEight
University of Leeds
Phase 2 Completed
NCT02412228 2025-10-15
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Brown University
Phase 2 Completed
NCT03731832 2025-09-30
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
GWT-TUD GmbH
Phase 2 Completed
NCT01415882 2025-09-05
Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
Mayo Clinic
Phase 2 Completed
NCT02916771 2025-08-11
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01864018 2025-07-24
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Phase 1/2 Completed
NCT02765854 2025-06-26
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
Emory University
Phase 2 Completed
NCT03770260 2025-06-19
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
National Cancer Institute (NCI)
Phase 1 Completed
NCT03012880 2025-06-04
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT03941860 2025-05-23
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
Phase 3 Completed
NCT03748953 2025-03-21
Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
Takeda
Phase 3 Completed
NCT02924272 2025-03-12
Ixazomib Rollover Study
Takeda
Phase 2 Completed
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT02921893 2025-02-12
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT01718743 2025-01-28
Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02181413 2024-11-19
A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant
Takeda
Phase 3 Completed
NCT03399539 2024-11-04
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
Mayo Clinic
Phase 1 Completed
NCT02633059 2024-09-19
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT04217967 2024-08-01
Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients
Peking Union Medical College Hospital
Phase 4 Completed
NCT03439293 2024-07-03
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda
Phase 2 Completed
NCT02697383 2024-05-13
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02586038 2024-05-08
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
University of Turin, Italy
Phase 2 Completed
NCT04028115 2024-04-03
BONE
Odense University Hospital
Phase 2 Completed
NCT02119468 2024-03-15
Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
City of Hope Medical Center
Phase 1/2 Completed
NCT03506360 2024-01-09
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT03169361 2023-12-07
NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"
Takeda
Completed
NCT02547662 2023-10-30
Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
Mayo Clinic
Phase 2 Completed
NCT02312258 2023-09-21
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
Takeda
Phase 3 Completed
NCT03202628 2023-09-21
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Completed
NCT01936532 2023-08-03
IFM2013-06
Nantes University Hospital
Phase 2 Completed
NCT01850524 2023-07-21
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Takeda
Phase 3 Completed
NCT01564537 2023-03-10
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 3 Completed
NCT02440464 2023-01-04
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT03236792 2022-09-29
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT02169791 2021-09-02
Nonmyeloablative Haploidentical Transplant Followed by MLN9708
Northside Hospital, Inc.
Phase 2 Completed
NCT02499081 2021-06-11
UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
University of Arkansas
Phase 2 Completed
NCT02831686 2020-11-24
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02504359 2020-11-23
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
OHSU Knight Cancer Institute
Phase 1 Completed
NCT02477215 2020-10-22
Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Medical College of Wisconsin
Phase 1/2 Completed
NCT01318902 2020-04-01
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
Takeda
Phase 1 Completed
NCT02168101 2020-02-27
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT02410694 2019-12-13
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT02057640 2019-12-11
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT00932698 2019-08-07
Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma
Takeda
Phase 1 Completed
NCT02046070 2019-07-17
Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 2 Completed
NCT01830816 2019-06-10
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
Takeda
Phase 1 Completed
NCT01383928 2019-03-21
Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma
Takeda
Phase 1/2 Completed
NCT01645930 2018-11-08
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
Takeda
Phase 1 Completed